

## Mini-Reviews in Medicinal Chemistry



**Title:**Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs

**VOLUME:** 17 **ISSUE:** 11

**Author(s):**Karina Vázquez, Margot Paulino, Cristian O. Salas, Juan J. Zarate-Ramos, Brenda Vera and Gildardo Rivera\*

**Affiliation:**Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Nuevo León, Escobedo, 66050, Centro de Bioinformática Estructural DETEMA, Facultad de Química, Universidad de la Republica, P.O. 1157, Montevideo, Departamento de Química Orgánica, Facultad de Química, Pontificia Universidad Católica de Chile, Santiago, 6094411, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Nuevo León, Escobedo, 66050, Centro de Bioinformática Estructural DETEMA, Facultad de Química, Universidad de la Republica, P.O. 1157, Montevideo, Centro de Biotecnología Genómica, Instituto Politecnico Nacional, Boulevard del Maestro, s/n, Esquina Elías Piña, Reynosa, 88710

**Keywords:**Chagas disease, trypanothione reductase, Trypanosoma cruzi, target, drugs, inhibitors.

**Abstract:**Background & Objective: Chagas disease or American trypanosomiasis is a major parasitic disease in Latin America with restricted available treatment: nifurtimox and benznidazole. These two drugs are ineffective in the chronic phase of the disease; therefore, there is a need for the development of new, efficient and safe drugs for the treatment of this pathology. With this goal, one of the promising targets is trypanothione reductase (TR), a key enzyme in the metabolism of Trypanosoma cruzi.

Conclusion: In this review, we analyse the importance of TR as a drug target, as well as the well-known and new inhibitors reported in the last decade as potential therapeutic agents for Chagas disease.

Close

Print this page